Patents Assigned to Gilead Sciences, Inc.
  • Patent number: 10800772
    Abstract: Compounds disclosed herein including compounds of Formula I: and salts thereof are provided. Pharmaceutical compositions comprising compounds disclosed herein, processes for preparing compounds disclosed herein, intermediates useful for preparing compounds disclosed herein and therapeutic methods for treating an HIV infection using compounds disclosed herein are also provided.
    Type: Grant
    Filed: September 26, 2017
    Date of Patent: October 13, 2020
    Assignee: Gilead Sciences, Inc.
    Inventors: Zhenhong R. Cai, Hongyan Guo, Mingzhe Ji, Haolun Jin, Amy Lee, Ryan McFadden, Michael L. Mitchell, Manuel Munoz, Hyung-Jung Pyun, Lianhong Xu, Hong Yang
  • Patent number: 10786518
    Abstract: The disclosure is directed to methods of treating subjects infected with HIV, once daily, with single unit dosage forms that include darunavir (or a hydrate or solvate thereof), cobicistat, emtricitabine, and a tenofovir prodrug, or salt thereof.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: September 29, 2020
    Assignees: Janssen Sciences Ireland UC, Gilead Sciences, Inc.
    Inventors: Katia Boven, Goedele De Smedt, Regina Driesen, Dominiek Henrist, Greet Kauwenberghs, Sandeep Mathur, Scott McCallister, Roel Mertens, Richard Nettles, Magda Opsomer, William Pyrz, Vahid Zia
  • Patent number: 10774053
    Abstract: The invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of Formula I, processes for preparing compounds of Formula I, therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS symptoms in a mammal using compounds of Formula I.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: September 15, 2020
    Assignee: Gilead Sciences, Inc.
    Inventors: Zhenhong R. Cai, Aesop Cho, Ana Zurisadai Gonzalez Buenrostro, Xiaochun Han, Salman Y. Jabri, Ryan McFadden, Yingmei Qi, Johannes Voigt, Hong Yang, Jie Xu, Lianhong Xu
  • Patent number: 10774071
    Abstract: Compounds and methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.
    Type: Grant
    Filed: July 12, 2019
    Date of Patent: September 15, 2020
    Assignee: Gilead Sciences, Inc.
    Inventors: Evangelos Aktoudianakis, Aesop Cho, Michael Graupe, Lateshkumar Thakorlal Lad, Paulo A. Machicao Tello, Jonathan William Medley, Samuel E. Metobo, Devan Naduthambi, Barton W. Phillips, Scott Preston Simonovich, Peiyuan Wang, William J. Watkins, Jie Xu, Kin Shing Yang, Christopher Allen Ziebenhaus
  • Patent number: 10774054
    Abstract: The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Grant
    Filed: August 14, 2019
    Date of Patent: September 15, 2020
    Assignee: Gilead Sciences, Inc.
    Inventors: Peter A. Blomgren, Kevin S. Currie, Christian Gege, Jeffrey E. Kropf, Jianjun Xu
  • Patent number: 10752636
    Abstract: The invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of Formula I, processes for preparing compounds of Formula I, therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS symptoms in a mammal using compounds of Formula I.
    Type: Grant
    Filed: March 26, 2019
    Date of Patent: August 25, 2020
    Assignee: Gilead Sciences, Inc.
    Inventors: Elizabeth M. Bacon, Elbert Chin, Jeromy J. Cottell, Ashley Anne Katana, Darryl Kato, John O. Link, Nathan Shapiro, Teresa Alejandra Trejo Martin, Zheng-Yu Yang
  • Patent number: 10745412
    Abstract: The present disclosure provides solid forms, including a salt or co-crystal, of Compound I: which exhibits Acetyl-CoA carboxylase (“ACC”) inhibitory activity and may be useful in treating ACC mediated diseases. Also provided herein are processes or steps for the preparation of a Compound I and intermediates useful for the processes or steps described herein.
    Type: Grant
    Filed: November 20, 2019
    Date of Patent: August 18, 2020
    Assignee: Gilead Sciences, Inc.
    Inventors: Luke Humphreys, Mark E. Scott
  • Publication number: 20200223907
    Abstract: Antibodies that bind to HIV gp120 and neutralize HIV are disclosed. Also disclosed are methods of using such antibodies alone or in combination with other therapeutic agents to treat or prevent HIV infection.
    Type: Application
    Filed: July 2, 2019
    Publication date: July 16, 2020
    Applicant: Gilead Sciences, Inc.
    Inventors: Mini Balakrishnan, Brian A. Carr, Magdeleine S. Hung, Manu Kanwar, Craig S. Pace, Doug Rehder, Matthew Robert Schenauer, Loredana Serafini, Heather Theresa Stephenson, Nathan D. Thomsen, Helen Yu, Xue Zhang
  • Patent number: 10710986
    Abstract: Compounds of Formula (I), methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.
    Type: Grant
    Filed: February 12, 2019
    Date of Patent: July 14, 2020
    Assignee: Gilead Sciences, Inc.
    Inventors: Evangelos Aktoudianakis, Aesop Cho, Zhimin Du, Michael Graupe, Lateshkumar Thakorlal Lad, Paulo A. Machicao Tello, Jonathan William Medley, Samuel E. Metobo, Prasenjit Kumar Mukherjee, Devan Naduthambi, Eric Q. Parkhill, Barton W. Phillips, Scott Preston Simonovich, Neil H. Squires, Peiyuan Wang, William J. Watkins, Jie Xu, Kin Shing Yang, Christopher Allen Ziebenhaus
  • Patent number: 10703733
    Abstract: The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: July 7, 2020
    Assignee: Gilead Sciences, Inc.
    Inventors: Hang Chu, Juan A. Guerrero, Anna E. Hurtley, Tae H. Hwang, Lan Jiang, Darryl Kato, Tetsuya Kobayashi, John E. Knox, Scott E. Lazerwith, Xiaofen Li, David W. Lin, Jonathan W. Medley, Michael L. Mitchell, Devan Naduthambi, Zachary Newby, Neil H. Squires, Vickie H. Tsui, Chandrasekar Venkataramani, William J. Watkins, Hong Yang
  • Patent number: 10695357
    Abstract: Provided are compounds, methods, and pharmaceutical compositions for treating Filoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula IV: The compounds, compositions, and methods provided are particularly useful for the treatment of Marburg virus, Ebola virus and Cueva virus infections.
    Type: Grant
    Filed: February 12, 2019
    Date of Patent: June 30, 2020
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Byoung Kwon Chun, Michael O'Neil Hanrahan Clarke, Edward Doerffler, Hon Chung Hui, Robert Jordan, Richard L. Mackman, Jay P. Parrish, Adrian S. Ray, Dustin Siegel
  • Patent number: 10696657
    Abstract: The present disclosure relates to methods and intermediates useful for preparing a compound of formula I: or a co-crystal, solvate, salt or combination thereof.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: June 30, 2020
    Assignee: Gilead Sciences, Inc.
    Inventors: Amanda L. Vandehey, Gediminas Brizgys, Vinh X. Ngo, Brian M. O'Keefe, Trevor J. Rainey, Bing Shi, Winston C. Tse, Anna M. Wagner, Xianghong Wang, Scott A. Wolckenhauer, Chloe Y. Wong
  • Patent number: 10695361
    Abstract: Provided are methods for treating Arenaviridae and Coronaviridae virus infections by administering nucleosides and prodrugs thereof, of Formula I: wherein the 1? position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Lassa virus and Junin virus infections.
    Type: Grant
    Filed: February 1, 2019
    Date of Patent: June 30, 2020
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Michael O'Neil Hanrahan Clarke, Joy Yang Feng, Robert Jordan, Richard L. Mackman, Adrian S. Ray, Dustin Siegel
  • Patent number: 10696679
    Abstract: Provided are methods for treating Paramyxoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula I: wherein the 1? position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Human parainfluenza and Human respiratory syncytial virus infections.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: June 30, 2020
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Richard L. Mackman, Jay P. Parrish, Adrian S. Ray, Dorothy Agnes Theodore
  • Patent number: 10689399
    Abstract: Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, X, W, Y1, Y2, Z1, and Z4 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: June 23, 2020
    Assignee: Gilead Sciences, Inc.
    Inventors: Elizabeth M. Bacon, Zhenhong R. Cai, Xiaowu Chen, Jeromy J. Cottell, Manoj C. Desai, Mingzhe Ji, Haolun Jin, Scott E. Lazerwith, Michael R. Mish, Philip Anthony Morganelli, Hyung-Jung Pyun, James G. Taylor, Teresa Alejandra Trejo Martin
  • Patent number: 10682368
    Abstract: Provided are methods of treating feline Coronavirus infections using carbanucleoside compounds having a 1?-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl) substituent, or a pharmaceutically acceptable salt thereof. An exemplary compound is (2R,3R,4S,5R)-2-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-carbonitrile.
    Type: Grant
    Filed: March 13, 2018
    Date of Patent: June 16, 2020
    Assignees: GILEAD SCIENCES, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Michel Joseph Perron, Niels C. Pedersen
  • Patent number: 10675296
    Abstract: The present disclosure provides a composition comprising Compound 1, or a pharmaceutically acceptable salt thereof, cyclodextrin, and, optionally, pH adjusting agents.
    Type: Grant
    Filed: July 10, 2018
    Date of Patent: June 9, 2020
    Assignee: GILEAD SCIENCES, INC.
    Inventor: Nate Larson
  • Patent number: 10668064
    Abstract: Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, X, Y1, Y2, or L are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: June 2, 2020
    Assignee: Gilead Sciences, Inc.
    Inventors: Mingzhe Ji, Scott E. Lazerwith, Hyung-Jung Pyun
  • Patent number: 10654827
    Abstract: The present disclosure relates to a compound of formula (Ia), (Ib), (IIa), and (IIb): which are useful in the treatment of a Retroviridae viral infection including an infection caused by the HIV virus.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: May 19, 2020
    Assignee: Gilead Sciences, Inc.
    Inventors: Michael Graupe, Steven J. Henry, John O. Link, Roland D. Saito, Scott D. Schroeder, Dimitrios Stefanidis, Winston C. Tse, Jennifer R. Zhang
  • Patent number: RE48150
    Abstract: The present invention relates to compounds of Formula (I): wherein X1, X2, X3, X4, X5, R, R1, R2 are as defined above. The compounds have apoptosis signal-regulating kinase (“ASK1”) inhibitory activity, and are thus useful in the treatment of ASK1-mediated conditions, including autoimmune disorders, inflammatory diseases, cardiovascular diseases, diabetes, diabetic nephropathy, cardio-renal diseases, including kidney disease, fibrotic diseases, respiratory diseases, COPD, idiopathic pulmonary fibrosis, acute lung injury, acute and chronic liver diseases, and neurodegenerative diseases. The invention also relates to pharmaceutical compositions comprising one or more of the compounds of Formula (I), and to methods of preparing the compounds of Formula (I).
    Type: Grant
    Filed: January 3, 2017
    Date of Patent: August 11, 2020
    Assignee: Gilead Sciences, Inc.
    Inventors: Britton Corkey, Gregory Notte, Jeff Zablocki